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Introduction: The objectives of this study were (1) to assess the
results of mediastinoscopy and mediastinal lymphadenectomy and
(2) to compare outcomes of surgical treatment with or without
neoadjuvant therapy in patients with non-small cell lung cancer who
are N2 negative on integrated positron emission tomography and
computed tomography (PET/CT).
Methods: This was a retrospective, single-institution review of
patients with non-small cell lung cancer who were N2 negative on
CT and PET/CT. All patients underwent mediastinoscopy; if N2
positive, patients underwent neoadjuvant therapy followed by pul-
monary resection, and if N2 negative, patients underwent pulmonary
resection with mediastinal lymphadenectomy.
Results: Between 2003 and 2007, there were 750 patients (547
men). Of these, 51 patients were N2 positive at mediastinoscopy and
then underwent neoadjuvant therapy (mediastinoscopy N2 group),
and 699 were N2 negative at mediastinoscopy and then underwent
mediastinal lymphadenectomy. Mediastinal lymphadenectomy re-
vealed that 635 had N0 or N1 disease (N2-negative group), and 64
had N2 disease (surgery N2 group). Overall 5-year survival was
73% for the N2-negative group, 44% for the surgery N2 group, and
47% for the mediastinoscopy N2 group. Disease-free 5-year survival
was 59% for the N2-negative group, 27% for the surgery N2 group,
and 29% for the mediastinoscopy N2 group.
Conclusions:We found that there were no significant differences in
overall and disease-free survivals between the surgery N2 group and
the mediastinoscopy N2 group. The benefit of neoadjuvant therapy
in patients with PET/CT-negative but mediastinoscopy-positive N2
disease should be confirmed by randomized studies.
Key Words: Non-small cell lung cancer, Mediastinoscopy, Inte-
grated positron emission tomography and computed tomography,
Neoadjuvant therapy.
(J Thorac Oncol. 2011;6: 336–342)
Integrated positron emission tomography (PET) with [18F]fluorodeoxyglucose (FDG) and computed tomography (CT)
has improved the accuracy of mediastinal staging for non-
small cell lung cancer (NSCLC).1,2 PET/CT can detect areas
of high FDG metabolic activity consistent with malignancy.3
Nevertheless, when the FDG uptake within lymph nodes is
not increased on PET/CT despite the presence of malignancy,
this suggests microscopic lymph node metastasis.1,2,4 If N2
diseases were detected by mediastinoscopy or mediastinal
lymphadenectomy in such patients who had neither enlarged
lymph nodes on CT nor FDG uptake on PET/CT, their
prognoses would be better than those of patients with N2
diseases demonstrated as bulky mediastinal nodal enlarge-
ment on CT or increased FDG uptake on PET/CT.5,6 Never-
theless, few studies have investigated the role of mediasti-
noscopy and treatment outcomes in this subgroup of patients
with minimal N2 disease, which is silent and not avid for
FDG on PET/CT.
Since the introduction of PET/CT, we have routinely
performed both PET/CT and mediastinoscopy for patients
with NSCLC before curative-intent surgery at our institution.
The objectives of this study were (1) to assess the results of
mediastinoscopy and mediastinal lymphadenectomy and (2)
to compare treatment outcomes of surgery with or without
neoadjuvant therapy in patients with NSCLC who are N2
negative on PET/CT.
PATIENTS AND METHODS
Study Population
This was a retrospective, single-institution study of
patients meeting the following criteria. Patients had to have
histologically proven NSCLC; have both PET/CT and medi-
astinoscopy performed; and were staged N0 or N1 on both
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CT and PET/CT. Patients who were staged N2, N3, or M1 on
CT or PET/CT were excluded. Patients who had N3 on
mediastinoscopy were excluded. Patients were excluded if
neoadjuvant therapy was performed despite a negative medi-
astinoscopy or if surgery was performed despite a positive
mediastinoscopy. Patients with double primary lung cancers
or a carcinoid were excluded. The study was reviewed and
approved by the Institutional Review Board of Samsung
Medical Center.
PET/CT Acquisition
Patients received an intravenous injection of 370 MBq
(10 mCi) of FDG. Scans were acquired with a PET/CT device
(Discovery LS; GE Healthcare, Milwaukee, WI) consisting of
an Advance NXi PET scanner and an eight-section Light-
Speed Plus CT scanner. The axes of both systems were
mechanically aligned, so that shifting the examination table
by 60 cm moved the patient from the CT into the PET gantry.
An unenhanced CT was performed from the head to the pelvic
floor according to a standardized protocol involving 140 kv, 80
mA, a tube-rotation time of 0.5 second per rotation, a pitch of 6,
and a section thickness of 5 mm, which was matched to the PET
section thickness. Immediately after CT, PET was performed in
the identical transverse field of view. The acquisition time for
PET was 5 minutes per table rotation. PET data sets were
reconstructed iteratively with an ordered subsets expectation
maximization algorithm and segmented attenuation correction
(two iterations, 28 subsets) and the CT data. Coregistered scans
were displayed by using eNTEGRA software.
CT and PET/CT Image Analysis
Lymph nodes greater than 10 mm in the short-axis
diameter on CT scans were considered malignant. Lesions
with high FDG uptake (higher than that of the surrounding
normal mediastinal structure or with a standardized uptake
value of 3.5) and with a distinct margin and a round shape
on PET/CT were considered malignant. Lesions with equiv-
ocally increased glucose uptake (to a level similar to that of
the surrounding normal mediastinal structure) and with a
morphologic appearance of lobar or bronchopneumonia at CT
were interpreted as benign.
Mediastinoscopy
All patients underwent cervical mediastinoscopy. Me-
diastinoscopic examinations were done by the standard tech-
nique to evaluate the lymph nodes of 2R, 2L, 4R, 4L, and the
subcarinal stations. All nodal stations were evaluated and
sampled unless no nodal tissue was present at that station. If
lymph nodes were identified, biopsies were performed re-
gardless of their appearance.
Treatment Modalities
When patients are confirmed to have N2 disease by
staging workup, the treatment policy depends on whether
tumors or lymph nodes are resectable. If tumors or lymph
nodes are considered unresectable, we usually recommend
definitive concurrent chemoradiation. If they are considered
potentially resectable, we plan to perform neoadjuvant che-
moradiation and then restage them to decide whether they
receive surgery. Neoadjuvant therapy included thoracic radi-
ation therapy (TRT) concurrent with chemotherapy. The TRT
dose was 45 Gy over 5 weeks (1.8 Gy/fraction/d, 5 fractions/
wk) using 10 mV x-rays. The TRT target volume included the
known gross and clinical disease plus adequate peripheral
margins. The chemotherapy regimens consisted of weekly
paclitaxel (50 mg/m2/wk intravenously [IV]) plus cisplatin
(25 mg/m2/wk IV) or weekly paclitaxel (50 mg/m2/wk IV)
plus carboplatin (area under the curve, 1.5/wk IV) for 5
weeks. The first dose of chemotherapy was to be delivered on
the first day of TRT. Restaging procedures with complete
clinical and radiologic evaluation including CT scans were
performed within 3 weeks after the completion of neoadju-
vant therapy. Surgical resection was planned at around 4
weeks after the completion of neoadjuvant therapy.
In the absence of N2 or N3 disease at mediastinoscopy,
patients immediately underwent pulmonary resection and
complete mediastinal lymph node dissection. Operative pro-
cedures included lobectomies, bilobectomies, sleeve resec-
tions, or pneumonectomies as indicated. Mediastinal lymph
node dissection consisted of en bloc resections of all nodes at
stations 2R, 4R, 7, 8, 9, and 10R for right-sided tumors and
nodes at stations 4L, 5, 6, 7, 8, 9, and 10L for left-sided
tumors. We usually performed postoperative radiotherapy in
the event of persistent histologically positive N2 lymph node,
positive multiple N1 lymph nodes, or positive resection
margin at the time of surgery. Patients undergoing surgery
were regularly evaluated by CT every 3 months for the first
2 years after surgery and then every 6 months thereafter. In
cases lost to follow-up, a telephone interview was conducted
to determine the late outcomes.
Statistical Analysis
Descriptive statistics were used to describe the patients’
characteristics and outcomes. Student’s t tests or Mann-Whitney
tests, depending on the normality of distribution, and the 2 test
or Fisher’s exact test were used to compare continuous and
categorical variables, respectively. One-way analysis of variance
was used to compare the continuous variables among three
groups. Overall survival (OS) was defined as time from the date
of mediastinoscopy to death from any cause. Disease-free sur-
FIGURE 1. Diagram summarizing the study population.
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vival (DFS) was defined as time from the date of mediastinos-
copy to recurrence or death. Survival curves were prepared using
the Kaplan-Meier method and compared univariately using the
log-rank test. To determine which factors were significantly
associated with survival, a multivariate analysis using Cox
proportional hazards model was performed. All statistical tests
were two-sided, with a significance level set at 0.05 and were
performed using Stata software version 10.0 (Stata, College
Station, TX).
RESULTS
Patient Characteristics
Between June 2003 and December 2007, there were
750 patients (547 men and 203 women). Of these, 51 patients
(7%) were N2 positive at mediastinoscopy and then under-
went neoadjuvant therapy (mediastinoscopy N2 group). The
remaining 699 patients (93%) who were N2 negative at
mediastinoscopy underwent pulmonary resection and medi-
astinal lymph node dissection. Of the 699 patients who
underwent surgery, 635 patients had N0 (n  490) or N1
(n  145) disease (N2-negative group), and 64 patients had
N2 disease (surgery N2 group) (Figure 1). As a result, the
negative predictive value of PET/CT and mediastinoscopy
was 84.7% and 91.5%, respectively. Patient characteristics
are summarized in Table 1. There was no significant differ-
ence in clinical and pathologic features between the surgery
N2 group and mediastinoscopy N2 group, except in patho-
logic T stage and N stage.
In the mediastinoscopy N2 group, all the patients com-
pleted the neoadjuvant therapy and then underwent surgery.
The overall response rate was 75%, including three patients
with complete response, 35 with partial response, and 13 with
stable disease (Table 2). Overall, 322 patients (43%) under-
went adjuvant treatment after surgery, and there was no
difference in the frequency of adjuvant therapy between the
TABLE 1. Baseline Clinical and Pathologic Characteristics (N  750)
Characteristics
N2-Negative Group
(n  635)
Surgery N2 Group
(n  64)
Mediastinoscopy N2
Group (n  51)
paNo. Percentage No. Percentage No. Percentage
Age, yr (mean) 61.5 (23–90) 59.1 (41–77) 56.2 (30–76) 0.106
Gender 0.355
Male 474 75 43 33 30 59
Female 161 25 21 67 21 41
Histology 0.055
SCC 264 42 19 30 9 18
ADC 304 48 39 61 41 80
LAC 29 4 2 3 0 0
Others 38 6 4 6 1 2
SUVmax of primary
tumor (mean)
11.9 13.2 10.9 0.23
Pathologic T stage 0.002
T0 0 0 0 0 5 10
T1 148 23 9 14 13 25
T2 405 64 40 62 28 55
T3 48 8 10 16 0 0
T4 34 5 5 8 5 10
Pathologic N stage 0.000
N0 490 77 0 0 16 31
N1 145 23 0 0 10 20
N2 0 0 64 100 25 49
Positive N2 station 0.055
Single — — 49 77 46 90
Multiple — — 15 23 5 10
a Comparison was done between the surgery N2 group and mediastinoscopy N2 group.
SCC, squamous cell carcinoma; ADC, adenocarcinoma; LAC, large cell carcinoma; SUVmax, maximum standardized uptake value.
TABLE 2. Results of Neoadjuvant Therapy in the
Mediastinoscopy N2 Group
Patients
No. Percentage
Surgery after neoadjuvant therapy 51 100
Response (radiologic)
Complete response 3 6
Partial response 35 69
Stable disease 13 25
Pathologic complete response 3 6
Pathologic downstaging 26 51
N2–N0 16 31
N2–N1 10 20
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surgery N2 group and mediastinoscopy N2 group. Details
about the extent of surgery and adjuvant treatment are pre-
sented in Table 3.
Treatment-Related Morbidity and Mortality
No unexpected toxicities or deaths were noted during
neoadjuvant therapy in the mediastinoscopy N2 group.
Twelve patients (2%), one patient (2%), and two patients
(4%) died during the postoperative period in the N2-negative
group, the surgery N2 group, and the mediastinoscopy N2
group, respectively. The cause of death included acute respi-
ratory distress syndrome in seven patients, pneumonia in
seven, and empyema in one (Table 4). Major postoperative
complications occurred in 104 patients (16%) of the N2-
negative group, in 15 (23%) of the surgery N2 group, and in
six (12%) of the mediastinoscopy N2 group (Table 4). There
was no significant difference in the treatment-related morbid-
ity (p  0.91) or mortality rate (p  0.43) among the three
groups.
OS and DFS
The median follow-up time was 40 months (range,
1–79 months), and 17 patients (2.3%) were lost to follow-up.
No significant differences were found in the follow-up dura-
tion (p  0.09) and follow-up loss rate (p  0.61) among the
three groups. At the end of follow-up, 556 patients were alive
(491 in the N2-negative group, 34 in the surgery N2 group,
and 31 in the mediastinoscopy N2 group). Median OS time
was not reached for the N2-negative group, whereas it was 45
months (95% confidence interval [CI], 30–60 months) for the
surgery N2 group and 59 months (95% CI, 43–75 months) for
the mediastinoscopy N2 group. Overall 5-year survival rate
was 73% for the N2-negative group, 44% for the surgery N2
group, and 47% for the mediastinoscopy N2 group (Figure
2A). There was no significant difference in OS between the
surgery N2 group and the mediastinoscopy N2 group (p 
0.49). Among the mediastinoscopy N2 group, overall 5-year
survival rate was 42% for patients who achieved mediastinal
clearance and 20% for those who have persistent lymph node
involvement after neoadjuvant therapy. Among the surgery
N2 group, there was no significant difference in overall
5-year survival between patients with right-sided lesions
TABLE 3. Summary of Treatment Modalities
N2-Negative Group
(n  635)
Surgery N2 Group
(n  64)
Mediastinoscopy N2
Group (n  51)
paNo. Percentage No. Percentage No. Percentage
Extent of resection 0.059
Lobectomy (VATSb) 476 (97) 75 43 (10) 67 45 (0) 88
Bilobectomy 42 7 7 11 3 6
Pneumonectomy 52 8 8 13 2 4
Sleeve lobectomy 64 10 6 9 1 2
Others 1 0.2 0 0 0 0
Completeness of resection 0.775
R0 620 98 61 95 48 94
R1 15 2 3 5 3 6
R2 0 0 0 0 0 0
Adjuvant treatment 0.498
Chemotherapy 170 27 13 31 10 20
Radiotherapy 63 10 14 20 24 47
Chemoradiation 7 1 17 22 4 8
Not done 395 62 20 27 13 25
a Comparison was done between the surgery N2 group and mediastinoscopy N2 group.
b The number of VATS lobectomy cases was expressed.
R0, no residual tumor; R1, microscopic residual tumor; R2, macroscopic residual tumor; VATS, video-assisted thoracic surgery.
TABLE 4. Summary of Postoperative Morbidity and
Mortality
No. (%)
N2-Negative
Group
(n  635)
Surgery
N2 Group
(n  64)
Mediastinoscopy
N2 Group
(n  51) pa
Overall in-hospital
mortality
12 (1.9) 1 (1.6) 2 (3.9) 0.43
ARDS 5 (0.8) 1 (1.6) 1 (2)
Pneumonia 6 (0.9) — 1 (2)
Empyema 1 (0.2) — —
Overall morbidity 104 (16) 15 (23) 6 (12) 0.91
ALI or ARDS 26 (4.1) 2 (3.1) 1 (2)
Pneumonia 5 (0.8) 2 (3.1) 2 (3.9)
Empyema  BPF 6 (0.9) — —
Atrial fibrillation 28 (4.4) 3 (4.7) 4 (7.8)
Prolonged air leak 21 (3.3) 5 (7.8) 3 (5.9)
Chylothorax 11 (1.7) 1 (1.6) —
Vocal cord palsy 13 (2) 2 (3.1) 1 (2)
Bleeding 2 (0.3) 1 (1.6) —
a Comparison was done between the three groups.
ARDS, acute respiratory distress syndrome; ALI, acute lung injury; BPF, broncho-
pleural fistula.
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(25%) and those with left-sided lesions (31%). Also, there
was no significant difference in the site of first recurrence
between the two groups.
During follow-up, 257 patients developed recurrence,
and there was no significant difference in the incidence of
recurrence between the surgery N2 group and mediastinos-
copy N2 group (p  0.79). Data regarding recurrence pattern
are summarized in Table 5. Median DFS time was not
reached for the N2-negative group, whereas it was 16 months
(95% CI, 9–22 months) for the surgery N2 group and 24
months (95% CI, 13–34 months) for the mediastinoscopy N2
group. Disease-free 5-year survival rate was 59% for the
N2-negative group, 27% for the surgery N2 group, and 29%
for the mediastinoscopy N2 group (Figure 2B). There was no
significant difference in DFS between the surgery N2 group
and the mediastinoscopy N2 group (p  0.39).
Multivariate Analysis for Mediastinoscopy N2
and Surgery N2 Groups
For patients with pathologic N2 disease (Surgery N2 
mediastinoscopy N2 groups), multivariate analysis were per-
formed and listed in Table 6. Histology other than adenocar-
cinoma or squamous cell carcinoma and pneumonectomy
were independent predictive factors associated with both OS
and DFS. Adjuvant treatment was also associated with in-
creased OS. Comparison of the survival curves according to
pneumonectomy and adjuvant therapy were depicted in Fig-
ures 3A, B, respectively.
DISCUSSION
In this retrospective study of patients who underwent
both PET/CT scans and mediastinoscopy for staging of
NSCLC, we excluded patients with bulky mediastinal lymph
nodes on CT and those with increased FDG uptake in the
mediastinum on PET/CT. This suggests that even if patients
with N2 disease detected at mediastinoscopy or mediastinal
lymphadenectomy were included, this study population rep-
resents patients with minimal N2 disease. There was no
significant difference in OS and DFS between patients who
underwent neoadjuvant therapy and those who did not un-
dergo neoadjuvant therapy.
These findings can be interpreted in two different ways,
depending on whether both the mediastinoscopy N2 group
and surgery N2 group represent the same population in terms
of mediastinal nodal status. If two groups represent the same
population, our results suggest that there might be no survival
benefit of neoadjuvant therapy in this subset of patients with
“PET/CT-negative” N2 disease. In other words, even if N2 is
unexpectedly detected at primary surgery, the outcomes
might be comparable with neoadjuvant therapy plus surgery
in this group. Several authors showed the favorable outcomes
of primary surgery for minimal N2 disease.6–12 Andre et al.6
reported a 5-year survival of 34% for 244 patients with
single-level minimal N2 disease who underwent primary
surgery. Ichinose et al.7 reported a 5-year survival of 43% for
209 patients who had not received neoadjuvant therapy and
were found to have single-level N2 disease. Presumably,
chemotherapy is mainly active on distant micrometastases
rather than locoregional lymphatic spread. The probability of
distant micrometastases in patients with minimal N2 disease
is likely to be low compared with clinical N2 disease. There-
fore, the role of neoadjuvant chemotherapy may have been
less obvious in patients with minimal N2 disease.
Nevertheless, if two groups represent different patient
populations, the absence of differences in survival could be
related to the therapeutic benefit of neoadjuvant treatment.
The fact that N2 disease was detected by mediastinoscopy in
the mediastinoscopy N2 group and not in the surgery N2
group implies that the mediastinoscopy N2 group might have
more extensive mediastinal nodal involvement than the sur-
gery N2 group. If it is true, comparable survivals of the
FIGURE 2. A, Overall survival according to subgroups. B, Disease-free survival according to subgroups.
TABLE 5. Summary of Recurrence Pattern
No. (%)
pa
N2-Negative
Group
(n  635)
Surgery
N2 Group
(n  64)
Mediastinoscopy
N2 Group
(n  51)
Overall recurrence 190 (29.9) 38 (59.4) 29 (56.9) 0.79
Locoregional 53 (8.4) 17 (26.6) 8 (15.7) 0.16
Distant 114 (20) 19 (29.7) 16 (31.4) 0.85
Locoregional  distant 23 (3.6) 2 (3.1) 5 (9.8) 0.24
a Comparison was done between the surgery N2 group and mediastinoscopy N2
group.
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mediastinoscopy N2 group with the surgery N2 group can be
attributed to the benefit of neoadjuvant therapy. Unfortu-
nately, however, it is nearly impossible to verify whether
there is truly a difference in the extent of mediastinal nodal
involvement or the probability of distant metastasis between
the two groups. Because the mediastinoscopy N2 group
already went through neoadjuvant therapy and their medias-
tinal nodes responded to the therapy, it would be inappropri-
ate to simply compare the findings obtained at mediastinal
nodal dissection between the two groups. Therefore, only a
randomized controlled trial where patients with PET/CT-
negative but mediastinoscopy-positive N2 disease would be
randomized to neoadjuvant therapy could really answer the
question about the role of neoadjuvant therapy in this subset
of patients.
As clearance of mediastinal node involvement is a
major prognostic factor, it is important to predict and identify
patients who experienced pathologic downstaging after neo-
adjuvant therapy. Nevertheless, whether restaging tests accu-
rately predict responders and which restaging test is best are
TABLE 6. Multivariate Association between Clinicopathologic Factors and Overall Survival or
Disease-Free Survival in the Mediastinoscopy N2 and Surgery N2 groups (N  115)
Factors
Overall Survival Disease-Free Survival
HR 95% CI P HR 95% CI p
Histology
ADC (n  80) 1 0.0001 1 0.0001
SCC (n  28) 0.37 0.13–1.03 0.056 0.43 0.2–0.93 0.032
Others (n  7)a 8.63 2.81–26.5 0.0001 5.01 1.83–13.8 0.002
Pathologic T stage
T0b (n  5) 1 0.002 1 0.23
T1 (n  22) 2.42 0.44–13.5 0.31 1.1 0.27–4.41 0.9
T2 (n  68) 0.94 0.19–4.71 0.94 1.03 0.28–3.79 0.97
T3 (n  10) 4.7 0.74–29.9 0.1 2.16 0.47–9.99 0.32
T4 (n  10) 4.6 0.75–28.7 0.1 2.17 0.49–9.6 0.3
Pathologic N stage
N0 (n  16) 1 0.41 0.06
N1 (n  10) 0.93 0.21–4.13 0.93 3.67 1.2–11.1 0.02
N2 (n  89) 2.0 0.58–6.88 0.27 1.75 0.63–4.86 0.29
Pneumonectomy
No (n  105) 1 0.0001 1 0.0001
Yes (n  10) 9.32 3.07–28.3 5.08 2.1–12.2
Neoadjuvant therapy
Not done (n  64) 1 0.239 1 0.84
Done (n  51) 1.73 0.69–4.32 0.93 0.46–1.87
Adjuvant therapy
Not done (n  33) 1 0.006 1 0.1
Done (n  82) 0.37 0.18–0.76 0.64 0.37–1.1
a Others included large cell carcinoma in three patients, sarcomatoid carcinoma in three patients, and adenosquamous cell carcinoma in
two patients.
b Pathologic complete response after neoadjuvant therapy.
HR, hazard ratio; CI, confidence interval; ADC, adenocarcinoma; SCC, squamous cell carcinoma.
FIGURE 3. A, Overall survival according to the extent of resection in patients who had pathologic N2 disease. B, Overall sur-
vival according to adjuvant therapy in patients who had pathologic N2 disease.
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still unclear.13 Although, the most commonly used method of
restaging is the radiographic response by CT or PET/CT, they
have relatively high false-negative and false-positive rates.
Remediastinoscopy could be reliable in terms of restaging
techniques, but it needs experienced surgeons to be feasible,
especially for patients who underwent neoadjuvant chemora-
diation and initial mediastinoscopy. Endobronchial ultra-
sound or endoscopic ultrasound tests are gradually becoming
more widely available, and these modalities seem to be prom-
ising for restaging in recent studies. Although we cannot defi-
nitely answer what modality would be the best in terms of
restaging, it is still important to perform surgery in selected
patients who undergo downstaging after neoadjuvant treatment.
In our series, the locoregional failure rate was 11%
higher in the surgery N2 group than in the mediastinoscopy
N2 group. This may be related to the difference in tumor
characteristics between the two groups. Although not statis-
tically significant, more patients had squamous cell carci-
noma in the surgery N2 group than in the mediastinoscopy
N2 group, which implies that patients of the surgery N2
group were more likely to have centrally extensive tumor
than those of the mediastinoscopy N2 group. This is also
related to the fact that patients from the surgery N2 group
more frequently received pneumonectomy, sleeve lobectomy,
or bilobectomy than the mediastinoscopy N2 group, although
not statistically significant. We suspect that these findings can
explain the reason why the locoregional failure rate was
rather higher in the surgery N2 group than in the mediasti-
noscopy N2 group.
Our study has several limitations. First, this is a retro-
spective study which has many intrinsic drawbacks. Second,
despite the fact that all the patients were N2 negative on
PET/CT, the study population consists of a heterogeneous
group of patients. Although statistically insignificant, the
methods of adjuvant treatment were not evenly distributed in
the study population. Also, the perioperative management
might have been changed during the study period. There was
significant difference in pathologic T and N stages between
the mediastinoscopy N2 group and surgery N2 group, even
though it is attributed to the effect of neoadjuvant therapy in
the mediastinoscopy N2 group. These limitations can be
overcome by prospective randomized trial. Third, we com-
bined the patients with N0 and N1 disease into the same
group, which might have influenced our results.
In conclusion, we retrospectively reviewed the out-
comes of patients with NSCLC who were N2 negative on
PET/CT. We compared the survival between patients who
underwent neoadjuvant therapy due to a positive mediasti-
noscopy and those who did not receive neoadjuvant therapy
based on a negative mediastinoscopy and were found to have
unexpected N2 disease at surgery. We found that there was
no significant difference in the OS and DFS between the two
groups. If two groups represent the same population, our
results suggest that there might be no survival benefit of
neoadjuvant therapy in this subset of patients with “PET/CT-
negative” N2 disease. Nevertheless, if two groups represent
different patient populations, comparable survivals between
two groups can be attributed to the benefit of neoadjuvant
therapy. Therefore, our results should be confirmed by ran-
domized prospective studies.
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